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Abstract
Background: Xenotropic murine leukemia virus-related virus (XMRV) was recently discovered to be the first human
gammaretrovirus that is associated with chronic fatigue syndrome and prostate cancer (PC). Although a mechanism for
XMRV carcinogenesis is yet to be established, this virus belongs to the family of gammaretroviruses well known for their
ability to induce cancer in the infected hosts. Since its original identification XMRV has been detected in several
independent investigations; however, at this time significant controversy remains regarding reports of XMRV detection/
prevalence in other cohorts and cell type/tissue distribution. The potential risk of human infection, coupled with the lack of
knowledge about the basic biology of XMRV, warrants further research, including investigation of adaptive immune
responses. To study immunogenicity in vivo, we vaccinated mice with a combination of recombinant vectors expressing
codon-optimized sequences of XMRV gag and env genes and virus-like particles (VLP) that had the size and morphology of
live infectious XMRV.
Results: Immunization elicited Env-specific binding and neutralizing antibodies (NAb) against XMRV in mice. The peak titers
for ELISA-binding antibodies and NAb were 1:1024 and 1:464, respectively; however, high ELISA-binding and NAb titers
were not sustained and persisted for less than three weeks after immunizations.
Conclusions: Vaccine-induced XMRV Env antibody titers were transiently high, but their duration was short. The relatively
rapid diminution in antibody levels may in part explain the differing prevalences reported for XMRV in various prostate
cancer and chronic fatigue syndrome cohorts. The low level of immunogenicity observed in the present study may be
characteristic of a natural XMRV infection in humans.
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Introduction
Xenotropic murine leukemia virus-related virus (XMRV) was
first identified through microarray analysis of human prostate
cancer (PC) samples from patients with an inherited defect in
RNASEL (R462Q variant), a downstream effector of the antiviral
interferon defense pathway [1,2]. The presence of gammaretro-
viral genomes was further confirmed by gag-specific nested RT-
PCR and FISH [2]. Based on sequence analysis, XMRV is closely
related to mouse exogenous gammaretroviruses that are known to
cause leukemias and lymphomas in different host species. Since its
original identification, XMVR has been detected in several
independent investigations. In one study XMRV was isolated
from the prostate carcinoma cell line 22Rv1 [3]. Multiple XMRV
chromosomal integration sites were found in the 22Rv1 cell line as
well as in that of cancer tissues of PC patients [4]. Although it does
not have common integration sites within or near proto-oncogenes
or tumor suppressor genes [3], XMRV shows preferences for
integration near cancer breakpoints, common fragile sites and
microRNA [4]. Additional evidence for XMRV came from a
study that analyzed a large cohort of patients with different stages
of PC as well as healthy men, which revealed the prevalence of
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aggressive tumors [5]. This study expanded the population of PC
patients infected with XMRV to include those with normal
RNASEL. Moreover, our recent publication further demonstrated
the prevalence of XMRV in prostate tissue derived from an
independent cohort of PC patients [6]. This study showed
concordance between the presence of neutralizing antibodies
(NAb) and XMRV nucleic acids detected by nested PCR and
FISH. Another independent study has shown that XMRV is
detectable in normal and tumor prostate tissue from patients with
PC from the southern United States [7]. In addition to being
identified in PC samples, evidence for XMRV was also found in a
study of subjects with Chronic Fatigue Syndrome (CFS) that
revealed the presence of XMRV in activated human B and T cells
as well as detectable levels of anti-XMRV Env antibodies in nine
out of 18 CFS human plasma samples [8]. In another recent
study, a second related polytropic MLV-like virus was detected in
separate cohort of 37 CFS subjects [9]. Collectively these studies
provide evidence for infection of humans by these newly identified
viruses that belong to a family of viruses that cause significant
pathogenesis in their natural hosts [2,5].
In contrast to the studies mentioned above, XMRV was not
found in PC and CFS patient cohorts from several European and
US studies. Studies of the prevalence of XMRV in two PC patient
cohorts in Germany found, for example, no link between prostate
cancer and the presence of XMRV when DNA or RNA from
tumor samples was analyzed [10,11]. Also, analyses of CFS
cohorts from England and Netherlands failed to detect XMRV
using PCR analysis [12,13,14]. Likewise, an ELISA-based screen
of antibodies in plasma of PC patients detected no XMRV-specific
responses [11] and no antibodies against XMRV were found in
sera of CFS patients when XMRV pseudoviruses were used in a
neutralization assay [12]. In a study from the Centers for Disease
Control and Prevention (CDC), there was no evidence of XMRV
infection in 50 CFS patients or 56 healthy controls [15]. Some
have speculated that geographical restrictions account for the
differences in detecting XMRV; however, the fact that the assays
and reagents varied among the studies described above may also
have contributed to the differences in findings. Thus, additional
investigations are needed to sort out those discrepancies and reveal
the true prevalence of XMRV infection.
In our recent study of XMRV serological prevalence in a cohort
of PC patients, we observed approximately 25% positivity for
serum XMRV antibodies [6]; however, despite this relatively high
incidence, the XMRV antibody titers were low overall compared
to those of HIV-1 infected individuals [16,17]. To provide an
explanation for the low magnitude of immune responses observed
in our PC cohort, we initiated a study of XMRV immune
responses in a murine model. We hypothesized that low
immunogenicity is an inherent characteristic of an XMRV
infection. To test this hypothesis, we vaccinated mice to elucidate
the magnitude and duration of the antibody response against the
XMRV Env antigen.
Results and Discussion
XMRV pseudovirus and NAb assay
An HIV-1 pseudovirus-based assay has been widely used for the
detection of NAb in sera from HIV-1 infected patients and
experimentally infected/vaccinated animal models [18,19]. We
therefore adapted the assay using an XMRV pseudovirus to
determine the utility of such an approach for detecting XMRV
NAbs. The infectivities of the XMRV and control HIV-1
pseudoviruses were compared by monitoring the levels of b-
galactosidase expression in TZM-BL cells after 48 hours of
infection (Figure 1A, black columns). The results indicated that
the XMRV pseudovirus is ,250 times more infectious than the
control HIV-1 pseudovirus. The difference in infectivity between
the two pseudoviruses was not due to de novo virus production,
since the p24 protein compositions of the XMRV and HIV-1
pseudoviruses were the same (Figure 1A, grey columns). It is likely
that the difference in infectivity is due to the codon-optimization
algorithm that was used to synthesize the XMRV env gene,
whereas the HIV-1 env gene used in this experiment was not
codon-optimized. We next determined whether the XMRV
pseudovirus could be employed in a NAb assay using monoclonal
antibodies (mAb) b12 and 83A25 (Figure 1B). The mAb b12,
which interacts with the CD4-binding site on the HIV-1 Env
glycoprotein, efficiently neutralized the HIV-1 pseudovirus but did
not neutralize the XMRV pseudovirus. Conversely, mAb 83A25,
which has been shown to neutralize several related MuLV strains
[20], inhibited infection of the XMRV pseudovirus in a dose-
dependent manner, but had no effect on the infectivity of HIV-1
pseudovirus. We then compared the XMRV and HIV-1
pseudoviruses in the NAb assay using polyclonal antibodies
(PAb) produced against Friend MuLV virus. The PAb neutralized
the XMRV pseudovirus over a wide dilution range, but did not
inhibit the HIV-1 pseudovirus at any dilution (Fig. 1C). The
neutralizing antibody titer that reduced XMRV infection by 50%
(NT50) was ,1:8300. Collectively, these data demonstrate that (1)
the XMRV Env can be pseudotyped onto HIV-1 viral particles
and that these XMRV pseudoviruses can (2) efficiently infect the
reporter cell line TZM-BL and (3) be used to detect XMRV-
specific antibodies with specificity and sensitivity over a wide range
of dilutions.
Characterization of XMRV expression vectors
To study XMRV immunogenicity in a mouse model, we next
generated plasmid and recombinant Ad5 vectors, called pDP1-
XMRVenvgag and Ad5-XMRV, respectively, that co-express the
XMRV gag and env genes. XMRV gag gene product expression was
determined by infecting HeLa cells with Ad5-XMRV, followed by
a Western blot analysis using mAb R187 [2], which showed the
Gag precursor at ,65 kDa (Lane 1, top arrow) and a cleaved
lower molecular mass Gag protein (Lane 1, bottom arrow) in the
cytosolic lysate (Fig. 2A). The latter is likely to be a product of non-
specific cleavage by host proteases, since the viral protease was not
expressed. Only the immature Gag protein was detected after
pelleting the media through a sucrose cushion (Lane 2), since VLP
do not contain virus specific proteases that are required for Gag
maturation. We also detected XMRV Env expression using mAb
83A25. Flow cytometric analysis of HeLa cells infected with Ad5-
XMRV detected surface and intracellular XMRV Env expression
(Fig. 2B left). The presence of XMRV Env in purified virus-like
particles (VLP) was indicated by Western blot analysis. (Fig. 2B
right).
It was shown previously that the infection of cells with Ad5
vectors that co-express HIV-1 gag and env genes leads to the
production of virus-like particles (VLP) [21]. Our XMRV VLP are
different from the virus in that they are not infectious since
infectivity requires Gag protein processing and virus maturation.
However, the Env protein is folded and exposed on the VLP in the
same way it is present on native virus. In this regard, using
transmission electron microscopy (TEM) we detected XMRV
VLP in HeLa cells infected with Ad5-XMRV (Fig. 2C, Panels I
and II). XMRV VLP budding was observed (Fig. 2C, Panel I) that
was comparable to virus budding from DU145-C7 cells that
produce infectious XMRV (Fig. 2C, Panels III and IV). We also
XMRV Immunogenicity in Murine Model
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(Fig. 2C, Panel I) and their dispersal throughout the cytosol of the
cells infected with Ad5-XMRV (Fig. 2C, Panel II). This
observation suggests that VLP may also assemble within
multivesicular bodies (MVP) in which case Env is recycled from
the plasma membrane and then interacts with Gag on the MVP
membrane [22]. The XMRV VLP were similar in size and
morphology (see Panel II and IV insets) to those observed in the
culture media of 22Rv1 cells [3] and DU145 cells transfected with
a full-length XMRV molecular clone [5]. Based on our data in
vitro, we predict that XMRV VLP production occurs in cells
infected with Ad5-XMRV in vivo after immunization.
Immunization of mice and detection of neutralizing sera
against XMRV
We next sought to determine whether immunization with the
XMRV VLP-expressing vectors would elicit an anti-Env antibody
response. Such VLP-based vaccinations against other viruses have
been efficacious [23,24,25,26] and may be important when the
antigenicity and immunogenicity of the Env protein are affected by
the structural context of the epitope(s) [27]. We used the
immunization scheme of DNA priming and Ad5 boosting that
has been successfully applied in multiple systems [28,29,30,31,32].
The Ad5 vector has been well characterized for efficient vaccine
delivery and is well suited for the co-delivery of multiple antigens
into the same cells. In addition, Ad5 vectors activate the innate
immune system initiating the production of pro-inflammatory
cytokines and differentiation of immature dendritic cells into
professional antigen-presenting cells [32]. Thus, we expected that
our DNA prime/Ad5 boost regiment would stimulate XMRV-
specific immune responses. To determine the immunogenicity of
XMRVEnv,Balb/Cmice(10animalspergroup)were primedwith
pDP1-XMRVenvgag plasmid on Day 0, and then boosted with
recombinant Ad5-XMRV at 22 and 50 days after priming. Binding
antibodies were detected after the first Ad5 boost then declined to
baseline within 20 days and were not boosted by a second Ad5
immunization (Fig. 3A). XMRV NAb were detected after the
plasmid DNA prime (Fig. 3B); however, they dropped to nearly
undetectable levelsin20 days and were not boosted bythe firstAd5-
XMRV vaccination. The second Ad5-XMRV boost modestly
increased the NAb activity by ,20%. The mice were then boosted
once again on Day 100 with XMRV VLP (7.5 mg per mouse). The
resulting binding antibodies and NAb were increased 6- and 3-fold,
respectively, but started to decrease (.20%) again by the end of the
experiment on Day 130 (Fig. 3A–B).
We next determined the titers of the serum samples collected at
peak (i.e., at 10 days after the XMRV VLP boost). The ELISA
end-point dilution titer for the immune sera was 1:512 (Fig. 3C)
and the NAb titer that inhibited infection by 50% (NT50) was
1:464 (Fig. 3D). The specificity of immune serum was further
assessed in a NAb assay using control HIV-1 pseudovirus (Fig. 3E).
Immune sera did not neutralize the negative control HIV-1
pseudovirus, but did neutralize the XMRV pseudovirus with high
efficiency at up to 1:540 dilution. It is important to note that the
only difference between these XMRV and HIV-1 pseudoviruses is
the Env protein; therefore, neutralizing activity detected in the
immune serum is primarily directed against XMRV Env rather
than against host cell proteins incorporated into the lipid
membrane, which can be major antibody targets when using
VLP- or virion-based immunogens produced in host cells from a
different species [33].
Immunization elicits XMRV NAb
We next purified total immunoglobulin (Ig) from the immune
and control sera to further characterize the serum neutralizing
activity. Similar to the results using sera, significant binding
activity was detected with purified Ig from the XMRV-immunized
group as compared to the control group (Fig. 4A). In addition, we
observed significant NAb activity in the XMRV-immunized
Figure 1. Characterization of XMRV pseudovirus and single-
round neutralization assay. (A) Comparison of XMRV and control
HIV-1 pseudoviruses in yield (p24 accumulation) and infectivity (IU/ml
on TZM-bl cells). (B) Detection of antibody specificity to XMRV and HIV-
1 pseudoviruses. Pseudoviruses were tested in the neutralization assay
with mAb 83A25 that recognizes a shared epitope of MLV Env
glycoprotein and with mAb b12 that recognizes HIV-1 Env glycoprotein.
(C) Neutralization of the XMRV and HIV-1 pseudoviruses showing a
broad range of sensitivity and specificity of the assay using polyclonal
antibodies (anti Friend-MuLV).
doi:10.1371/journal.pone.0018272.g001
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PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18272Figure 2. Expression of XMRV Env, Gag and VLP. (A) Western blot analysis of XMRV gag expression. HeLa cells were infected with Ad5-XMRV
(10 MOI) for 24 h and then whole cell lysate (Lane 1) and cell culture media concentrated 100-fold by centrifugation through a 20% sucrose cushion
(Lane 2) were subjected to 10% SDS-PAGE and then transferred to PVDF. The blots were probed with anti-Gag mAb R187 and HRP-conjugated goat
anti-rat immunoglobulin G antiserum (Southern Biotechnology Associates, Inc.). The masses (kDa) of the molecular weight standards (Std) are shown
on the left. The arrows (r) indicate the positions of the Gag precursor at ,65 kDa (top arrow) and a cleaved, lower molecular mass Gag protein
(bottom arrow). (B) Detection of XMRV envelope expression by flow cytometric (left) and Western blot (right) analyses. For flow cytometry, HeLa cells
infected as in (A) were stained with mAb 83A25 and fluorescein isothiocyanate-conjugated goat anti-rat immunoglobulin G antiserum. For Western
blot analysis, VLP produced by those cells were purified from culture media and probed with mAb 83A25. MAb 83A25 recognizes an epitope located
near the carboxyl terminus of Env that common for many MuLVs. (C) Electron microscopy showing VLP production in HeLa cells after 48 hours of
infection with Ad5-XMRV (Panels I and II). An infectious XMRV virus is shown budding (arrows) from Du145-C7 cells, a prostate cancer cell line that
constitutively produces XMRV (Panels III and IV). The similarities in morphology and size between the VLP and live XMRV particles are in the insets of
Panels II and IV.
doi:10.1371/journal.pone.0018272.g002
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18272Figure 3. Detection of XMRV-specific antibody production in mouse sera. Time course of the production of (A) ELISA-binding antibodies
and (B) NAb in Balb/C mice (10 animals in each group) immunized with pDP1-XMRVenvgag (first arrow; P), Ad5-XMRV (second and third arrows; A)
and XMRV VLP (fourth arrow; V). Determination of (C) endpoint dilution and (D) serum neutralizing titers at the peak time point indicated by asterisks
in Panels A and B, respectively. The arrow indicates endpoint dilution. (E) The specificity of the serum neutralizing activity was determined by
comparing XMRV and HIV-1 pseudoviruses and showed that the primary target for neutralization is the XMRV Env.
doi:10.1371/journal.pone.0018272.g003
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concentration in the control group (Fig. 4B). Thus, delivery of
XMRV antigens clearly elicits a humoral immune response in
mice that leads to the production of XMRV-specific binding
antibodies and NAb.
Although we were able to elicit XMRV Env antibodies, the
magnitude of the response was lower than that observed following
immunization with other retrovirus VLP [34]. Though speculative
at this point, there are several possibilities to explain this result.
One explanation is that glycosylation of the Env proteins could
conceal some of the antigenic sites necessary for the host to mount
a robust neutralizing immune response, as this is known to occur
with other retroviruses [35]. It is also possible that partial tolerance
due to the presence of endogenous murine retroviruses may have
diminished the immunogenicity of the XMRV Env protein in the
mouse model that we used here. In this regard, it has been shown
that human and murine endogenous retroviruses can account for
the lack of immunogenicity of some tumor-associated viral
antigens [36]. To test this possibility we are currently investigating
XMRV immunity in rabbit and non-human primate models.
Another possibility is that the XMRV Env has immunosuppressive
activity that reduces its immunogenicity, which has been shown
with related murine and primate Env proteins [37,38,39]. With
these considerations in mind, ongoing studies are underway to
optimize the immunization regime.
Discrepancies among current reports on XMRV prevalence,
and gaps in what is known about its role in transformation,
transmission and pathogenesis, provide an impetus for basic
investigation of XMRV and the development of standardized
detection assays. We undertook the present study in order to
determine the immunogenicity of the XMRV Env in an
experimental model and, in the process, developed ELISA and
NAb assays for measuring anti-XMRV immunity. Here we
demonstrate that the XMRV Env protein is immunogenic in a
mouse model but that the resulting antibody responses are low in
magnitude and short in duration. We have previously observed
similarly low levels of XMRV antibodies in a study of 40 PC
patients [6] and in an expanded cohort of nearly 300 PC patients
(unpublished). The results of our current study are also in line with
those of a recent report of XMRV infection in a non-human
primate model [40]. That study revealed a pattern of relatively low
antibody induction following the initial XMRV infection, and
showed that this was only modestly boosted by a second infection
158 days later. Moreover, the antibody titers in that study
decreased after both the prime and boost infections using live
XMRV. While there was clearly a deficiency in eliciting a durable
antibody response, the roles(s) of (i) possible replicative deficiencies
of the virus in these primate hosts [41], (ii) immunosuppressive
activity of the viral proteins [37,38,39] and/or (iii) host restriction
factors [42,43] will require further investigation. Another recent
study reported the induction of XMRV NAbs using Gairdner’s
shrew-mice (Mus pahari) that express a functional XPR1 receptor
and support a productive XMRV infection [41]. Using this model
may provide opportunities to evaluate XMRV with regard to its
pathogenesis, replication and vaccine-induced protection from
infection. Lastly, our study raises the possibility that low
immunogenicity may be an intrinsic characteristic of XMRV,
which could in part account for some of the reported discrepancies
in detecting XMRV in various patient cohorts.
Conclusions
In summary, binding and neutralizing antibody responses
elicited by XMRV VLP vaccination in a mouse model were
characterized. The antibody titers decreased rapidly after
immunization, which may be an intrinsic feature of XMRV
immunogenicity. The relatively low and gradually decreasing
humoral immune responses we observed may in part explain the
low titers of antibodies detected in PC patients and the
discrepancies among reports of XMRV seroprevalence in different
cohorts of patients.
Methods
Cells lines
HeLa, Du145, Du145-C7, 293-AD and 293T cells were grown
in DMEM supplemented with 10% FBS (CellGro). The Du145-
C7 cell line that produce infectious XMRV was provided by Dr.
R.H. Silverman (The Cleveland Clinic, Cleveland, OH). TZM-bl
cells were obtained from the National Institutes of Health AIDS
Research and Reference Reagent Program (Catalog number
8129). TZM-bl cells express CD4 and co-receptors, CCR5 and
Figure 4. Characterization of antibodies purified from immune
and control mouse sera. Total immunoglobulin pool was affinity
purified from immune or control sera collected at the peak time point
of neutralizing activity (figure 3B). The ELISA-binding (A) and NAb (B)
activities were then measured as described in Figure 3 and showed that
immunization elicited an immune response leading to the production
of anti-XMRV immunoglobulins.
doi:10.1371/journal.pone.0018272.g004
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genes for firefly luciferase and Escherichia coli b-galactosidase under
control of an HIV-1 long-terminal repeat sequence [44,45,46].
The 293-AD cell line, derived from HEK293 cells with improved
cell adherence and plaque forming properties, was purchased from
Stratagene (Cat. No. 240085; La Jolla, CA, USA).
Plasmids and recombinant Ad5 vectors
Codon optimized sequences of XMRV gag and env (GenBank
accession numbers JF309078 and JF309077, respectively) were
synthesized by GenScript Corporation (Piscataway, NJ) and
cloned into pUC57 vector. The env sequence was then cloned
into the first CMV-driven expression cassette of pDP1 Shuttle
vector using AgeI and XbaI restriction enzymes, resulting in the
plasmid pDP1-XMRVenv. The XMRV gag gene was cloned into
the second MCMV-driven expression cassette of the pDP1-
XMRVenv using EcoRI and HindIII, resulting in pDP1-
XMRVenvgag. The details and complete sequences of pDP1,
pDP1-XMRVenv and pDP1-XMRVenvgag are available upon
request. Finally, pDP1-XMRVenvgag was recombined with the
pAdEasy-1 plasmid by co-transfection into 293-AD cells using
Lipofectamine 2000 to produce the recombinant Ad5, Ad5-
XMRV. The control Ad5 vector, Ad5-Luc, which expresses the
luciferase gene was produced in a similar manner and described
previously [47]. The recombinant Ad5 vectors were purified by
double centrifugation on cesium chloride gradients and subjected
to dialysis as described [48]. The physical titers, or total virus
particles (VP), were determined spectrophotometrically by mea-
suring the OD at 260 nm where 1 absorbance unit is equivalent to
1.1610
12 virus particles [49]. Viral titers were determined by a
standard 50% tissue culture infectious dose (TCID50) assay using
293-AD cells. The TCID50 was converted to plaque forming units
(PFU) per ml where the PFU/ml has been empirically determined
to be 0.7 log less that the TCID50/ml.
Production of HIV and XMRV pseudoviruses and XMRV
VLP
Pseudoviruses were produced by co-transfecting into 293T cells
the plasmid pSG3DEnv (AIDS Research and Reference Reagent
Program; Catalog Number 11051; [46,50]) with plasmids
expressing either the HIV-1 or XMRV env (pDP1-XMRVenv)
gene. Virus containing cell media was collected after 48 hours of
infection. Infectivity of XMRV and HIV-1 pseudoviruses was
compared by detection of beta-galactosidase expression 48 hours
after infection of TZM-bl cells.
To produce XMRV VLP, HeLa cells were infected (10 MOI)
with Ad5-XMRV in DMEM with 2% FBS for 16 hours for virus
absorption and then the media was replaced with fresh growth
media. Culture media was then collected after 48 hours of
infection, passed through a 0.45- mm filter (Whatman, Florham
Park, NJ) and concentrated ,1,000 times by ultracentrifugation at
25,000 xg through 20% sucrose in PBS buffer. Purified VLP were
stored in aliquots after total protein concentration was detected
and subsequently used for immunization of mice and for coating
ELISA plates and immunoblotting.
Immunization
For immunization, 10 Balb/c mice (Charles River) were first
primed with DNA (25 mg of pDP1-XMRV plasmid per mouse in
50 ml of Saline) and then boosted 22 and 50 days later with Ad5-
XMRV (2610
9 virus particles per mouse in 100 ml of Saline).
Mice were then boosted again on Day 100 with XMRV VLP
(7.5 mg per mouse in 50 ml of Saline). All immunizations were
done intramuscularly in femoral muscle. The control mice were
primed with the same amount of empty plasmid and boosted with
adenoviruses expressing the beta-galactosidase gene.
Neutralization assay
Monoclonal antibodies (mAb 83A25 and mAb b12; AIDS
Reference and Reagent Program, Catalog No. 2640), polyclonal
antibodies (Goat anti-Friend MLV, ATCC catalog # VR-
1537AS-Gt) and mouse sera were assayed for the presence of
neutralizing activity against XMRV pseudoviruses using a single-
round pseudotype reporter assay described previously [19]. The
monoclonal antibody mAb 83A25 was a kind gift from Dr.
Leonard Evans (NIAID NIH, Rocky Mountain Laboratories).
Briefly, TZM-bl cells were plated and cultured overnight. A total
of 2,000 infectious units of pseudotyped virus were combined with
fivefold dilutions of heat-inactivated test serum and incubated for
1 hour at 37uC. Noninfectious heat-inactivated mouse serum was
added as necessary to maintain a constant overall concentration.
The virus-antibody mixture was then added to TZM-bl cells, and
after two days, the cells were lysed, and the luciferase activity of
each well was measured using a luciferase assay reagent (Promega,
Madison, WI) and a Synergy HT luminometer (Bio-Tek,
Winooski, VT). Background luminescence was determined in
uninfected wells and subtracted from all experimental wells. Cell
viability and toxicity were monitored by basal levels of luciferase
expression and by visual inspection. Relative neutralization
(percentage of control) was calculated by dividing the number of
luciferase units at each serum dilution by the values in wells
containing no test serum and subtracting that value from the
values in wells containing no test serum. The dilution of antibody
or sera that neutralizes infection by 50% (NT50) was then
calculated using the GROWTH function in Excel version 12.2.5.
Immunoassays
XMRV ELISA. For detection of XMRV-specific antibodies in
mouse sera, an indirect ELISA was performed. XMRV VLP
(3 mg/ml) in CB2 buffer (Immunochemistry Technologies LLC,
Bloomington, MN) was immobilized on Immunoplates
(NAlgeNunc, Rochester, NY), according manufacturer protocol,
and incubated with serial dilutions of mouse sera. Specific
antibodies were detected with goat anti-mouse HRP-conjugated
IgG (H+L) (Southern Biotech, Birmingham, AL) and OPD
substrate (Thermo Science, Rockford, IL). Mouse polyclonal
antibodies were purified from mouse sera using Nab Protein A/G
Spin Kit (Thermo Scientific, Rockford, IL) that allows small-scale
affinity purification of antibodies from serum. The endpoint titer is
defined as the reciprocal of the highest dilution of a serum that
gives a reading above the cutoff. Cutoff was calculated for each
dilution using equation Cutoff = X*SDf, where X is average and
SD is standard deviation values measured for control serum, and f
is SD multiplier corresponding to the confidence level 95% and
number of replicates [51].
HIV-1p24 ELISA. Extracellular p24 was measured using the
Alliance HIV-1 p24 ELISA kit (Perkin-Elmer) according to the
manufacturer’s instructions. Cell-free supernatants from infected
cultures were harvested and stored at -80uC prior to
quantification.
Immunoblotting
Immunoblotting was performed using ether cell lysate after
infection with Ad5 vector or purified VLP. Samples were
separated by 12% SDS-PAGE, transferred to Immun-Blot
TM
PVDF membrane (Bio-Rad, Hercules, CA), blocked with 5% BSA
in TBS-T buffer (50 mM Tris, 150 mM NaCl, 0.05% Tween-20,
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[52] or 83A25 anti-Env monoclonal antibody [53]. R187 antibody
has been shown to react with XRMV Gag [1,4] and 83A25
antibody weakly recognizes a common epitope in SU of gamma-
retroviral envelope proteins [53]. After incubation with secondary
antibody, HRP-conjugated anti-rat IgG (Southern Biotech,
Birmingham, AL), protein bands were visualized with enhanced
chemiluminescence detection reagents (Amersham Pharmacia).
Flow cytometry
For flow cytometry analysis of XMRV env gene expression
HeLa cells infected with 10 MOI of adenoviral vector for 48 hours
were permeabilized with Cytofix/Cytoperm (BD Bioscience) at
4uC for 20 min. After washing three times with Perm Wash Buffer
(BD Bioscience), cells were incubated with 1:10 dilution of mAb
83A25 [53] cell culture media at 4uC for 30 min. Cells were then
washed again and incubated with 1:200 diluted FITC-conjugated
goat anti-rat IgG (Southern Biotech, Birmingham, AL) at 4uC for
30 min. Cells were washed and analyzed on FACSCalibur flow
cytometer (BD Bioscience). Data were acquired with CellQuest
software and analyzed with FlowJo version 8.8.6 software.
Transmission electron microscopy (TEM) to detect XMRV
and XMRV VLP
Transmission electron microscopy was performed at the Emory
Robert P. Apkarian Integrated Electron Microscopy Core as
described previously [54]. Approximately 10
6 XMRV or XMRV
VLP infected HeLa cells were pelleted, then treated as a cell block:
fixed initially in 2.5% buffered glutaraldehyde, postfixed in 1%
osmium tetroxide in the same buffer, and dehydrated through
graded ethanol. The fixed cells were infiltrated with propylene
oxide and embedded in Embed-812 (Electron Microscopy
Sciences, Fort Washington, PA). Ultrathin sections (60–70 nM)
were cut examined using an H-7500 transmission electron
microscope (Hitachi, Pleasanton, CA).
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